Brief: Vistagen Initiates Fasedienol Repeat Dose Study For The Acute Treatment Of Social Anxiety Disorder
10/01/2025 14:02
Jan 10 (Reuters) - VistaGen Therapeutics Inc VTGN.O :
* VISTAGEN INITIATES FASEDIENOL REPEAT DOSE STUDY FOR THE
ACUTE
TREATMENT OF SOCIAL ANXIETY DISORDER
Source text: urn:newsml:reuters.com:*:nBw1vC7gBa
Further company coverage: VTGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vistagen Therapeutics
See all newsBrief: Vistagen TherapeuticsSays Fasedienol Nasal Spray Well-Tolerated With No New Drug-Related Safety Findings After 12 Months
VistaGen Q1 revenue rises on licensing agreement expiration
Brief: VistaGen Q1 EPS USD -0.3
Vistagen Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Vistagen Appoints Douglas J. Williamson To Its Board Of Directors